Betaadrenoblockers: new or well-known old?
Abstract
Cardiovascular diseases claim more than 4 million lives every year. In the general array of various drugs for the treatment of CVD, a separate niche is occupied by betaadrenoblockers. The level of sympathetic activity is an independent predictor of both total and cardiovascular mortality.
Despite the fact that betaadrenoblockers have long been known, they remain relevant in the treatment of various diseases and at the present time, especially in certain categories of patients (pregnant women, patients with chronic heart failure, acute and chronic coronary syndromes, chronic kidney disease).
The article analyzed the current literature and recommendations on the prevention and treatment of cardiovascular diseases from the perspective of the use of the article analyzed the current literature and recommendations on the prevention and treatment of cardiovascular diseases from the perspective of the use of betaadrenoblockers.
About the Authors
O. Galtsova
Институт повышения квалификации и переподготовки кадров здравоохранения УО «Белорусский государственный медицинский университет»
Belarus
Belarus
A. Zakharenko
Институт повышения квалификации и переподготовки кадров здравоохранения УО «Белорусский государственный медицинский университет»
Belarus
Belarus
T. Borovaya
Институт повышения квалификации и переподготовки кадров здравоохранения УО «Белорусский государственный медицинский университет»
Belarus
Belarus
References
1. Compelling indications should be listed for individual beta-blockers (due to diversity), not for the whole class / G. Koracevic, S. Micic, M. Stojanovic [et al.] // Current Vascular Pharmacology. — 2021. — Vol. 19, № 4. — P. 343—346.
2. Beta-blocker efficacy across different cardiovascular indications : an umbrella review and metaanalytic assessment / O. J. Ziff, M. Samra, J. P. Howard [et al.] // BMC Medicine. — 2020. — Vol. 18, № 1. — DOI: 10.1186/s12916-020-01564-3.
3. Dulin, B. Beta-blockers in heart failure / B. Dulin, W. T. Abraham // American Journal of Cardiology. — 2004. — Vol. 93, Suppl. 1. — P. 1—82.
4. Feuerstein R., Yue T.L. Mechanisms of beta-blocker action in hypertension // Pharmacology. — 1994. — Vol. 48. — P. 385—391.
5. Limited effect of systemic β-blockade on sympathetic outflow / J. Tank, A. Diedrich, C. Schroeder [et al.] // American Journal of Hypertension. — 2001. — Vol. 38, № 6. — P. 1377—1381.
6. Перепеч, Н. Б. Место бета-адреноблокаторов в фармакотерапии артериальной гипертензии. Обзор литературы / Н. Б. Перепеч, В. Д. Шурыгина // Вестник Санкт-Петербургского университета. Сер. 11. Медицина. — 2014. — Т. 11, № 1. — С. 76—86.
7. Шляхто, Е. В. Вегетативная нервная система и артериальная гипертензия / Е. В. Шляхто, А. О. Конради, В. А. Цырлин. — СПб. : Медицинское изд-во, 2008. — 312 с.
8. Механизмы антигипертензивного действия бета-адреноблокаторов / Э. В. Кулешова, Н. В. Кузьменко, М. Г. Плисс, В. А. Цырлин // Артериальная гипертензия. — 2021. — Т. 27, № 3. — С. 291—299.
9. Sympathetic outflow to muscles during treatment of hypertension with metoprolol / B. G. Wallin, G. Sundlof, E. Stromgren, H. Aberg // Hypertension. — 1984. — Vol. 6, № 4. — P. 557—562.
10. Arterial pressure lowering effect of chronic atenolol therapy in hypertension and vasoconstrictor sympathetic drive / J. Burns, D. A. Mary, A. F. Mackintosh // Hypertension. — 2004. — Vol. 44, № 4. — P. 454—458.
11. Use of opposing reflex stimuli and heart rate variability to examine the effects of lipophilic and hydrophilic β-blockers on human cardiac vagal control / J. C. Vaile, J. Fletcher, M. Al-Ani [et al.] // Clinical Science (Lond). — 1999. — Vol. 97, № 5. — P. 585—593.
12. Acute and long-term studies of the mechanisms of action of β-blocking drugs in lowering blood pressure / K. O. Stumpe, R. Kolloch, H. Vetter [et al.] // American Journal of Medicine. — 1976. — Vol. 60, № 6. — P. 853—865.
13. Mechanism of renin inhibition by β adrenergic blocking agents / T. Saruta, T. Eguchi, R. Nakamura [et al.] // Japanese Heart Journal. — 1980. — Vol. 21, № 1. — P. 103—109.
14. Multicenter evaluation of the hemodynamic effects of bisoprolol in patients with mild to moderate hypertension / L. M. Prisant, A. A. Carr, M. Desnoyers [et al.] // Journal of Clinical Pharmacology. — 1990. — Vol. 30, № 12. — P. 1096—1101.
15. Педли, Т. Гидродинамика крупных кровеносных сосудов / Т. Педли. — М. : Мир, 1983. — 400 с.
16. Согласованное мнение российских экспертов по оценке артериальной жесткости в клинической практике / Ю. А. Васюк, С. В. Иванова, Е. Л. Школьник [и др.] // Кардиоваскулярная терапия и профилактика. — 2016. — Т. 15, № 2. — C. 4—19.
17. Lund-Johansen, P. Haemodynamic long-term effects of metoprolol at rest and during exercise in essential hypertension / P. Lund-Johansen, O. J. Ohm // British Journal of Clinical Pharmacology. — 1977. — Vol. 4, № 2. — P. 147—151.
18. Morgan, T. Effect of carvedilol and metoprolol on blood pressure, blood flow, and vascular resistance / T. Morgan, R. Snowden, L. Butcher // Journal of Cardiovascular Pharmacology. — 1987. — Vol. 11. — P. 124—129.
19. Long-term reduction of peripheral resistance with celiprolol and effects on left ventricular mass / B. Trimarco, G. Lembo, N. De Luca [et al.] // Journal of International Medical Research. — 1988. — Vol. 16, № 1. — P. 62A—72A.
20. Башмаков, Ю. Э. Бета-адреноблокаторы и хроническая болезнь почек : литературный обзор / Ю. Э. Башмаков, А. Н. Федосеев, В. Е. Денисова // Качественная клиническая практика. — 2023. — № 4. — С. 58—77.
21. Hundemer, G. L. β-blockers in hemodialysis: simple questions, complicated answers / G. L. Hundemer, M. M. Sood, M. Canney // Clinical Kidney Journal. — 2020. — Vol. 14, № 3. — P. 731—734.
22. Segall, L. Heart failure in patients with chronic kidney disease : a systematic integrative review / L. Segall, I. Nistor, A. Covic // BioMed Research International. — 2014. — Vol. 2014. — DOI: 10.1155/2014/937398.
23. Bakris, G. L. Beta blockers in the management of chronic kidney disease / G. L. Bakris, Р. Hart, Е. Ritz // Kidney International. — 2006. — Vol. 70, № 11. — P. 1905—1913.
24. Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy / G. Cice, L. Ferrara, A. D'Andrea [et al.] // Journal of the American College of Cardiology. — 2003. — Vol. 41, № 9. — P. 1438—1444.
25. Effects of beta-adrenergic antagonists in patients with chronic kidney disease / S. V. Badve, M. A. Roberts, C. M. Hawley [et al.] // Journal of the American College of Cardiology. — 2011. — Vol. 58, № 11. — P. 1152—1161.
26. Comparison of the effects of angiotensin converting-enzyme inhibitors and beta blockers on survival in elderly patients / M. G. Shlipak, W. S. Browner, H. Noguchi [et al.] // The American Journal of Medicine. — 2001. — Vol. 110, № 6. — P. 425—433.
27. Sinha, A. D. Clinical pharmacology of antihypertensive therapy / A. D. Sinha, R. Agarwal // Clinical journal of the American Society of Nephrology. — 2019. — Vol. 14, № 5. — P. 757—764.
28. β-Blocker use in long-term dialysis patients / K. C. Abbott, F. C. Trespalacios, L. Y. Agodoa [et al.] // Archives of internal medicine. — 2004. — Vol. 164, № 22. — P. 2465—2471.
29. Catecholamine modulation of rapid potassium shifts during exercise / M. E. Williams, E. V. Gervino, R. M. Rosa [et al.] // The New England Journal of Medicine. — 1985. — Vol. 312, № 13. — P. 823—827.
30. Increase in serum potassium caused by beta-2 adrenergic blockade in terminal renal failure / P. Arrizabalaga, J. Montoliu, A. Martinez Vea [et al.] // Proceedings of the European Dialysis and Transplant Association. — 1983. — Vol. 20. — P. 572—576.
31. Randomised controlled trial of enalapril and beta blockers in non-diabetic chronic renal failure / T. Hannedouche, P. Landais, B. Goldfarb [et al.] // BMJ. — 1994. — Vol. 309, № 6958. — P. 833—837.
32. Differential effects of enalapril and atenolol on proteinuria and renal haemodynamics / A. J. Apperloo, D de Zeeuw, H. E. Sluiter, P. E. de Jong // BMJ. — 1991. — Vol. 303, № 6806. — P. 821—824.
33. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease / J. T. Wright, G. Bakris, T. Greene [et al.] // Journal of the American Medical Association. — 2002. — Vol. 288, № 19. — P. 2421—2431.
34. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II) : a randomised trial // Lancet. — 1999. — Vol. 353, № 9146. — P. 9—13.
35. Effect of metoprolol CR/XL in chronic heart failure (MERIT-HF) // Lancet. — 1999. — Vol. 353, № 9169. — P. 2001—2007.
36. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS) / M. D. Flather M. C. Shibata, A. J. S. Coats [et al.] // The European Heart Journal. — 2005. — Vol. 26, № 3. — P. 215—225.
37. Eichhorn, E. J. The carvedilol prospective randomized cumulative survival (COPERNICUS) trial / E. J. Eichhorn, M. R. Bristow // Current Controlled Trials in Cardiovascular Medicine. — 2001. — Vol. 2, № 1. — P. 20—23.
38. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure / M. Packer, M. R. Bristow, J. N. Cohn [et al.] // New England Journal of Medicine. — 1996. — Vol. 334, № 21. — P. 1349—1355. — DOI:10.1056/NEJM199605233342101.
39. 2021 Update to the 2017 ACC expert consensus decision pathway for optimization of heart failure treatment / Writing Committee ; T. M. Maddox, L. J. James, L. A. Allen [et al.] // Journal of the American College of Cardiology. — 2021. — Vol. 77, № 6. — P. 772—810.
40. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure / A. Hjalmarson, S. Goldstein, B. Fagerberg [et al.] // Journal of the American Medical Association. — 2000. — Vol. 283, № 10. — P. 1295—1302.
41. Clinical outcomes in patients on beta-blocker therapy admitted with worsening chronic heart failure / Gattis W.A., Ch. M. O'Connor, J. D. Leimberger [et al.] // American Journal of Cardiology. — 2003. — Vol. 91, № 2. — P. 169—174.
42. Protective effects of bisoprolol against myocardial injury and pulmonary dysfunction in patients with chronic heart failure / S. Toyoda, A. Haruyama, Sh. Inami [et al.] // International Journal of Cardiology. — 2017. — Vol. 226. — P. 71—76.
43. Switching from carvedilol to bisoprolol ameliorates adverse effects in heart failure patients with dizziness or hypotension / T. Taniguchi, T. Ohtani, I. Mizote [et al.] // Journal of Cardiology. — 2013. — Vol. 61, № 6. — P. 417—422.
44. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction / S. D. Solomon, J. J. V. McMurray, I. S. Anand [et al.] // New England Journal of Medicine. — 2019. — Vol. 381, № 17. — P. 1609—1620.
45. Mineralocorticoid Receptor Antagonists and Empagliflozin in Patients With Heart Failure and Preserved Ejection Fraction / J. P. Ferreira, J. Butler, F. Zannad [et al.] // Journal of the American College of Cardiology. — 2022. — Vol. 79, № 12. — P. 1129—1137.
46. Association of β-Blocker Use With Heart Failure Hospitalizations and Cardiovascular Disease Mortality / D. N. Silverman, T. B. Plante, M. Infeld [et al.] // JAMA Network Open. — 2019. — Vol. 2, № 12. — DOI: 10.1001/jamanetworkopen.2019.16598.
47. Impact of sex and myocardial function on association of obesity with mortality in Asian patients with acute heart failure / C. S. Park, un-Bean Park, Jin Joo Park [et al.] // BMJ Open. — 2020. — Vol. 10, № 2. — DOI: 10.1136/bmjopen-2019-031608.
48. Dar, J. A. Beta Blockers in Contemporary Cardiology / J. A. Dar, J. R. Jacob // Korean Circulation Journal. — 2024. — Vol. 54, № 4. — P. 165—171.
49. Роль бета-блокаторов в лечении сердечно-сосудистых заболеваний / В. С. Чулков, М. З. Гасанов, О. В. Азовцева [и др.] // Медицинский совет. — 2024. — № 16. — С. 28—36.
Review
For citations:
Galtsova O., Zakharenko A., Borovaya T. Betaadrenoblockers: new or well-known old? Healthcare. 2025;1(10):36-44. (In Russ.)
Views:
11
Email this article 